Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 11/20 | 0.58 |
| ▸ | CTSB | P07858 | 10/20 | 0.58 |
| ▸ | CTSS | P25774 | 9/20 | 0.58 |
| ▸ | CTSK | P43235 | 6/20 | 0.58 |
| ▸ | CTSF | Q9UBX1 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CTSV | O60911 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6061905 | 0.96 | CTSL (0.62) | CTSLCTSBCTSSCTSKCTSF | |
| SCHEMBL6062078 | 0.92 | CTSL (0.58) | CTSLCTSBCTSSCTSKCTSF | |
| SCHEMBL6737785 | 0.90 | CTSL (0.58) | CTSLCTSBCTSSCTSKCTSF | |
| SCHEMBL6742310 | 0.90 | CTSL (0.58) | CTSLCTSBCTSSCTSKCTSF | |
| SCHEMBL6744072 | 0.87 | CTSL (0.52) | CTSLCTSBCTSSCTSKCTSF | |
| SCHEMBL6062629 | 0.87 | CTSL (0.55) | CTSLCTSBCTSSCTSKCTSF | |
| SCHEMBL6062317 | 0.86 | CTSB (0.52) | CTSLCTSBCTSSCTSKCTSF | |
| SCHEMBL7548636 | 0.86 | CTSB (0.52) | CTSLCTSBCTSSCTSKCTSF | |
| SCHEMBL7551659 | 0.85 | CTSL (0.51) | CTSLCTSBCTSSCTSKCTSF | |
| SCHEMBL6063169 | 0.85 | CTSL (0.52) | CTSLCTSBCTSSCTSKCTSF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040014796-A1 | Novel compounds and compositions as cathepsin S inhititors | AXYS PHARMACEUTICALS, INC. | 2004-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014796-A1 | Novel compounds and compositions as cathepsin S inhititors | CTSS, CTSB, CTSE | CTSL 10/4885CTSB 2/4885CTSS 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.